Association between estimated glomerular filtration rate slope and cardiovascular disease among individuals with and without diabetes: a prospective cohort study

Table 3 Adjusted HRs for study outcomes according to the eGFR and its categories in subjects with diabetes (n = 985)

			Model 1		Model 2		Model 3
	Events/n	Incidence rate per 1000 person-years (95% CI)	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	P trend*
The slope of eGFR (mL/min/1.73 m² per year)			0.51 (0.12–2.11)	0.357	0.50 (0.11–2.18)	0.359	0.28 (0.05–1.42)	0.125
Quintiles of the slope of eGFR
Q5 (-0.5198, -0.1679)	50/197	37.8 (28.6–49.9)	Reference		Reference		Reference		0.010
Q1 (-1.0579, -0.7456)	22/197	14.5 (9.5–22.0)	1.63 (0.88–3.02)	0.118	1.65 (0.88–3.11)	0.116	2.16 (1.09–4.26)	0.026
Q2 (-0.7454, -0.6711)	35/197	24.1 (17.3–33.5)	1.83 (1.10–3.05)	0.019	1.92 (1.15–3.22)	0.011	2.39 (1.38–4.12)	0.002
Q3 (-0.6706, -0.6054)	36/197	24.8 (17.9–34.4)	1.39 (0.86–2.25)	0.176	1.36 (0.83–2.21)	0.211	1.54 (0.92–2.55)	0.094
Q4 (-0.6053, -0.5203)	52/197	39.5 (30.1–51.8)	1.61 (1.07–2.43)	0.021	1.56 (1.03–2.37)	0.033	1.76 (1.14–2.70)	0.009

Model 1 was adjusted for sex + age
Model 2 was adjusted for model 1 + BMI + smoking status + hypertension + hypercholesterolemia + FH-CVD + marital status + education level + FPG + glucose lowering drugs
Model 3 was adjusted for model 2 + eGFR at baseline (index date) + RAAS-I drugs + NPDR
* The p-value for the trend was computed in Model 3.
HR: hazard ratio; eGFR: estimated glomerular filtration rate; CI: confidence interval; BMI: body mass index; FH-CVD: family history of CVD; FPG: fasting blood glucose; NPDR: non-proliferative and proliferative diabetic retinopathy; RAAS-I: renin-angiotensin-aldosterone system inhibitors

ISSN: 1475-2840